MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
IPO Year: 2003
Exchange: NASDAQ
Website: meipharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | Buy → Hold | Laidlaw | |
| 3/25/2022 | $4.00 → $1.00 | Buy → Hold | Jefferies |
| 3/25/2022 | $13.00 → $2.00 | Overweight → Equal Weight | Wells Fargo |
| 3/25/2022 | $6.00 → $2.00 | Buy → Hold | Stifel |
| 2/3/2022 | $4.00 | Buy | Jefferies |
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
10-Q - MEI Pharma, Inc. (0001262104) (Filer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
10-Q - MEI Pharma, Inc. (0001262104) (Filer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
DEFA14A - MEI Pharma, Inc. (0001262104) (Filer)
DEF 14A - MEI Pharma, Inc. (0001262104) (Filer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
8-K - MEI Pharma, Inc. (0001262104) (Filer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4/A - MEI Pharma, Inc. (0001262104) (Issuer)
4/A - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
3 - MEI Pharma, Inc. (0001262104) (Issuer)
3 - MEI Pharma, Inc. (0001262104) (Issuer)
3 - MEI Pharma, Inc. (0001262104) (Issuer)
4 - MEI Pharma, Inc. (0001262104) (Issuer)
Laidlaw downgraded MEI Pharma from Buy to Hold
Jefferies downgraded MEI Pharma from Buy to Hold and set a new price target of $1.00 from $4.00 previously
Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously
Stifel downgraded MEI Pharma from Buy to Hold and set a new price target of $2.00 from $6.00 previously
Jefferies initiated coverage of MEI Pharma with a rating of Buy and set a new price target of $4.00
HC Wainwright resumed coverage of MEI Pharma with a rating of Buy and set a new price target of $10.00
Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c
Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme
Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been c
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process. In order to best preserve the Company's existing cash, the Company will commence a reduction-in-force beginning as soon as practicable and continuing in stages as the Company's operational
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritization of Voruciclib Program Development-- -- MEI Begins Fourth Fiscal Quarter with $56.6 Million in Cash -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company's Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Development of a New Formulation with the Potential to Increase Biological Activity, Patient Convenience and Commercial Opportunity – MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b
MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time. Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section of the Company's investor relations website https://investor.meipharma.com. A replay of the webcast will be made available following the event. About MEI Pharma M
– Enrollment Initiated in 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax in Ongoing Phase 1 Study – – Anti-leukemic Activity Across Multiple Heavily Pretreated Patients Demonstrated Along with Anticipated Decreases in Mcl-1 – – No Evidence of Overlapping Toxicity, and No Dose Limiting Toxicities Observed to Date in Dose Escalation Cohorts – MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selec
SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)
Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c
Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme
Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritization of Voruciclib Program Development-- -- MEI Begins Fourth Fiscal Quarter with $56.6 Million in Cash -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events. "In the ongoing clinical studies for both voruciclib, our oral CDK9 inhibitor, and ME-344, our inhibitor of mitochondrial oxidative phosphorylation, we are gratified by strong investigator support and enrollment that remains on-track, and we look forward to preliminary study read-outs in the near future," said David M. Urso, president and chief executive officer of MEI Pharma. "We are planning
MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events. "Our ongoing clinical studies evaluating the combination of voruciclib, our CDK9 inhibitor, with Venclexta in relapsed/refractory AML patients and ME-344, our mitochondrial inhibitor, combined with Avastin in metastatic colorectal cancer patients, continue to have strong investigator support and cohort enrollment remains on track in each program," said David M. Urso, president and chief executive officer of
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company's Board of Directors today declared a special cash dividend (the "Dividend") of $1.75 per share of common stock, $0.00000002 par value, payable on December 6, 2023 to stockholders of record at the close of business on November 17, 2023. The Company expects 100% of the special dividend to be characterized for tax purposes as return of capital to shareholders. About MEI Pharma MEI Pharma, Inc. (NASDAQ:MEIP) is a clinical-stage
Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") and Anson Funds and Cable Car Capital ("Anson and Cable Car") today announced that they have entered into a cooperation agreement. Key terms of the agreement include: Capital Return to Stockholders: The Company intends to promptly pay a dividend in the amount of $1.75 per share of common stock to all stockholders. Additionally, a second return of capital of approximately $9.33 million in the aggregate will be authorized by the Board if either (i) at least 17 patients in Cohort 1 of the Company's ongoing ME-34
- Responds to Substantial Stock Accumulation by Anson Advisors and Cable Car Capital - - Protects Long-Term Value of All Stockholders' Investments in MEI Pharma - MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan ("Rights Plan") under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances. The Board of Directors resolved to adopt the Rights Plan following the recent Schedule 13D amendments filed by Anson Advisors Inc. ("Anson Advisors") an
-- Conference Call Today at 5:00 p.m. Eastern Time -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023. "Over just the next few quarters we look forward to data readouts from two ongoing clinical studies of voruciclib and ME-344, advancing our strategy of assessing drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs," said David M. Urso, president and chief executive officer of MEI Pharma. "Focusing on the execution of these two clinical studies – voruciclib evaluated in co
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.
MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En
MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Mr. Sujay Kango to its board of directors effective November 22, 2021. "We are very happy to welcome Sujay, an industry leader with considerable commercialization and operational experience, to the MEI board as the company continues to exercise its vision to bring new therapies for cancer to patients," said Christine A. White, M.D., chairman of the board, MEI Pharma. "As MEI prepares to transition to a commercial stage company, and grow its clinical pipeline, we greatly look forward to benefiting from the more than 25 years of industry insigh
SAN DIEGO, July 7, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Tina C. Beamon, J.D., as chief compliance officer, effective immediately. Ms. Beamon will be responsible for the enterprise-wide compliance programs that manage risks associated with core business activities. "With her expert legal counsel and leadership, Tina strengthens our leadership team by bringing new knowledge and experience to guide MEI as we prepare for the potential commercialization of zandelisib, our lead drug candidate," said David M. Urso, J.D., chief operating officer and general counsel a
SAN DIEGO, April 30, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the retirement of Robert Mass, M.D., MEI's chief medical officer. Dr. Mass joined the company in 2010 and will retire on May 3, 2021, after which he will continue to serve as a strategic advisor to the company. The Company also announced that Richard Ghalie, M.D., MEI's senior vice president, clinical development, has been promoted to chief medical officer. "Bob's contributions to MEI over his more than ten years at the company have been invaluable across our drug candidate pipeline, particularly in guiding the st